Drugs / Fostrox
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07493668 | May 2026 → Apr 2028 expected | hepatocellular carcinoma | CHA University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fostrox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07493668 ↗ |
| Route | Oral | “Fostrox is an orally administered troxacitabine monophosphate prodrug designed to achieve selective activation within hepatocytes.” NCT07493668 ↗ |